Quote:

---

There is a mouse study investigating combination therapy of CCR2/CCR5 antagonist and FGF21 analogue which suggested an additive effect.

---

I've read those results using cencriviroc. I should have expounded and said I was looking for any direct effects of CCR5 on FGF21. Cencriviroc being a CCR2/CCR5 blockade drug is not a direct comparison to leronlimab. Cencriviroc has low occupancy for CCR5 and does little for CCL5 (RANTES) or CCR5 specific ligand downregulation. In the past I've read posts about a possible combo with leronlimab but as I've stated it would not be good to completely shut down the actions of other receptors or proteins.